Active — Not RecruitingNot Applicable

Quality of Life In Patients With Allergic Conjunctivitis In Treatment With Sublingual Allergen Immunotherapy In A Referral Ophthalmological Hospital

Mexico100 participantsStarted 2014-03-24

Plain-language summary

The goal of this observational study is to evaluate both clinical changes and quality-of-life outcomes in patients with allergic conjunctivitis treated with allergen-specific immunotherapy, integrating objective clinical parameters and validated quality-of-life measures to obtain a comprehensive view of the therapeutic impact.

Who can participate

Age range6 Years – 86 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient records containing complete information * Both sexes * Age range: 6 to 86 years * Between 2018 and 2023 * Diagnosed with allergic conjunctivitis * Who have received treatment with allergen-specific sublingual immunotherapy * With 8 assessments from the immunology and cornea department * With 7 quality of life questionnaires completed by the patient Exclusion Criteria: * Patient records for other inflammatory ocular conditions * Those with chronic diseases * Those who have received naturopathic or immunomodulatory treatment during the follow-up period for allergen-specific sublingual immunotherapy

What they're measuring

Quality of life evaluated by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Spanish version for Mexico in patients with Allergic Conjunctivitis treated with sublingual allergen immunotherapy.

Timeframe: Before Sublingual Immunotherapy

Quality of life in patients with Allergic Conjunctivitis treated with sublingual allergen immunotherapy evaluated using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Spanish version for Mexico.

Timeframe: From enrollment to the end of the 6th month of Allergen Immunotherapy treatment

Quality of life in patients with Allergic Conjunctivitis treated with sublingual allergen immunotherapy using Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Spanish version for Mexico.

Timeframe: From enrollment until 3 years of treatment with sublingual immunotherapy

Trial details

NCT IDNCT07149298

SponsorInstituto de Oftalmología Fundación Conde de Valenciana

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-10-09

View on ClinicalTrials.gov More Allergic Conjunctivitis of Both Eyes trials